BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Asia-Pacific’s largest specialist biotech CRO Novotech said many countries in the region were now fast-tracking their COVID-19 clients’ clinical trials with expedited review processes for treatment and vaccine candidates.

European Commission designated Orphan Drug status for ATH434’s treatment of Multiple System Atrophy in the European Union

Mateon Therapeutics Inc. report several peer-reviewed publications derived from its R&D effort against COVID-19..

Global health service company Cigna Corporation continues to lead a rapid response to the challenges presented by COVID-19 and reported strong first quarter 2020 results driven by focused execution across its businesses.

ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated intrabodies highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in amyotrophic lateral sclerosis, frontotemporal dementia and several other neurologic disorders.

GAAP earnings per share was $0.32; Operating EPS¹ was $0.59. Operating EPS excludes significant items in the quarter, totaling $0.27 per share, related to restructuring and asset related charges; early extinguishment of debt; and integration and separation costs.

GAAP revenue of $1,163.4 million for the three months ended March 31, 2020, representing growth of 4.0%, 3.8% on an adjusted basis, and 4.4% on a constant currency adjusted basis compared to the same period in 2019.

BIOLASE, Inc., the global leader in dental lasers, announced that it will release first quarter 2020 financial and operating results on Thursday, May 7, 2020 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments..